Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

THERMO FISHER SCIENTIFIC

(TMO)
  Report
Real-time Estimate Cboe BZX  -  10:07 2022-09-27 am EDT
509.48 USD   -0.94%
09/22Thermo Fisher Scientific Partners with Pennsylvania Biotechnology Center to Support Life Sciences Growth in Philadelphia
AQ
09/21Thermo Fisher Scientific Opens Biomanufacturing Facility in Massachusetts
MT
09/20Thermo Fisher Scientific : Invests $160 Million to Expand Bioproduction Capacity in Greater Boston
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : Expands Cell Culture Media Manufacturing Site in Grand Island New York

08/04/2022 | 08:09am EDT
Thermo Fisher Scientific Expands Cell Culture Media Manufacturing Site in Grand Island, New York

$76 million investment increases the site's capacity to produce critical raw materials used in the development and manufacturing of vaccines and biologic therapies

GRAND ISLAND, N.Y., Aug. 4, 2022 - To meet increasing global demand for cell culture media used in the manufacturing of new vaccines and biologics, Thermo Fisher Scientific has expanded its dry powder media manufacturing facility in Grand Island, New York. With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site's capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies. The Grand Island expansion is part of Thermo Fisher's $650 million multi-year investment, announced last year, to ensure flexible, scalable and reliable bioprocessing production capacity exists for these important medicines, including for COVID-19 vaccines.

The Grand Island expansion adds more than 45,000 square feet of Animal Origin Free (AOF) manufacturing space. This includes manufacturing of Thermo Fisher's Advanced Granulation Technology (AGT) format and other AOF Dry Powder Media (DPM) products. This additional capacity and reliability will help accelerate the development and production of lifesaving and life-changing biotherapeutics and vaccines by biopharmaceutical manufacturers, biotechnology developers and contract development and manufacturing organizations (CDMOs) in the global production markets of innovative biologics, biosimilars, cell therapies and viral vectors. This strategic investment has duplicated the existing manufacturing facility, process capabilities and equipment to provide production redundancy and shorten product manufacturing lead times for customers.

"Our expanded Grand Island site represents a significant milestone in our investment to double our total manufacturing capacity by the end of 2023," said Kate Torchilin, Ph.D, president, biologicals and chemicals, Thermo Fisher Scientific. "With the harmonized capabilities of our global manufacturing sitesthat enable us to prove equivalency in manufacturing, we're able to support current demand while priming for future growth and continuously enhancing our customer experience globally."

For 60 years, Grand Island has been home to Gibco products, which are essential for reliable, high quality biomanufacturing worldwide. Thermo Fisher's Gibco cell culture media and supplements are already used or have been used to develop and manufacture more than 250 commercial biologics, including cell and gene therapies, mAbs, and vaccines.

"The story of Thermo Fisher's presence on Grand Island speaks to the longstanding positive reputation of the biomedical research community in Western New York," said congressman Brian Higgins. "Gibco, originally founded by researchers at Roswell Park, continues to provide critical products to laboratories in our country and around the world, and the value of their work has been highlighted by the COVID-19 pandemic. Now employing over 1,600, I am proud to share in the celebration of Thermo Fisher's continued investments and commitment to the community in Western New York."

The expansion of the Grand Island site will add an estimated 100 team members across roles spanning R&D, operations, manufacturing, HR, engineering and maintenance. Thermo Fisher currently employs more than 1,600 people at the Grand Island site and over 3,000 people across New York.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Media Contact Information:

Chance Shay

Phone: 442-888-7797

Email: chance.shay@thermofisher.com

Anuj Baveja

Phone: 551-587-2233

Email: anuj.baveja@fleishman.com

SOURCE Thermo Fisher Scientific

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.

Disclaimer

Thermo Fisher Scientific Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 12:07:32 UTC.


© Publicnow 2022
All news about THERMO FISHER SCIENTIFIC
09/22Thermo Fisher Scientific Partners with Pennsylvania Biotechnology Center to Support Lif..
AQ
09/21Thermo Fisher Scientific Opens Biomanufacturing Facility in Massachusetts
MT
09/20Thermo Fisher Scientific : Invests $160 Million to Expand Bioproduction Capacity in Greate..
PU
09/14THERMO FISHER SCIENTIFIC : Ex-dividend day for
FA
09/13Thermo Fisher Scientific Collaborates with Taiwan Precision Medicine Initiative to Geno..
CI
09/12Barclays Cuts Thermo Fisher Scientific's Price Target to $595 From $685, Keeps Overweig..
MT
09/12Transcript : Thermo Fisher Scientific Inc. Presents at Morgan Stanley 20th An..
CI
09/12Thermo Fisher Scientific Certifies Applies Biosystems QuantStudio 7 Pro Dx Real-Time PC..
CI
09/07Thermo Fisher Scientific to Present at Morgan Stanley 2022 Global Healthcare Conference
BU
08/30Thermo Fisher Scientific Launches CE-IVD Next-Generation Sequencing Test and Analysis S..
AQ
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 199 M - -
Net income 2022 6 924 M - -
Net Debt 2022 24 596 M - -
P/E ratio 2022 29,4x
Yield 2022 0,23%
Capitalization 202 B 202 B -
EV / Sales 2022 5,23x
EV / Sales 2023 5,02x
Nbr of Employees 130 000
Free-Float 88,7%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 514,31 $
Average target price 658,24 $
Spread / Average Target 28,0%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC-21.95%201 501
DANAHER CORPORATION-20.17%191 071
INTUITIVE SURGICAL, INC.-47.70%67 112
BOSTON SCIENTIFIC CORPORATION-8.43%54 917
EDWARDS LIFESCIENCES CORPORATION-35.48%51 821
SIEMENS HEALTHINEERS AG-36.49%45 093